Compare Glenmark Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PFIZER - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PFIZER GLENMARK PHARMA/
PFIZER
 
P/E (TTM) x 11.9 33.4 35.7% View Chart
P/BV x 1.7 5.6 30.4% View Chart
Dividend Yield % 0.6 0.6 93.4%  

Financials

 GLENMARK PHARMA   PFIZER
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
PFIZER
Mar-18
GLENMARK PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs7122,365 30.1%   
Low Rs4841,625 29.8%   
Sales per share (Unadj.) Rs349.6430.3 81.3%  
Earnings per share (Unadj.) Rs32.878.7 41.7%  
Cash flow per share (Unadj.) Rs44.393.2 47.6%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.31.0 33.4%  
Book value per share (Unadj.) Rs198.6586.5 33.9%  
Shares outstanding (eoy) m282.1745.75 616.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.6 36.9%   
Avg P/E ratio x18.225.3 71.9%  
P/CF ratio (eoy) x13.521.4 63.0%  
Price / Book Value ratio x3.03.4 88.4%  
Dividend payout %6.125.4 24.0%   
Avg Mkt Cap Rs m168,62591,271 184.8%   
No. of employees `00012.02.6 457.7%   
Total wages/salary Rs m20,5613,143 654.2%   
Avg. sales/employee Rs Th8,196.07,484.8 109.5%   
Avg. wages/employee Rs Th1,708.11,195.0 142.9%   
Avg. net profit/employee Rs Th768.51,369.1 56.1%   
INCOME DATA
Net Sales Rs m98,65519,685 501.2%  
Other income Rs m2,0811,143 182.1%   
Total revenues Rs m100,73620,828 483.7%   
Gross profit Rs m15,8585,003 317.0%  
Depreciation Rs m3,259663 491.9%   
Interest Rs m3,3464 79,664.3%   
Profit before tax Rs m11,3355,479 206.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7561,878 200.0%   
Profit after tax Rs m9,2503,601 256.9%  
Gross profit margin %16.125.4 63.2%  
Effective tax rate %33.134.3 96.7%   
Net profit margin %9.418.3 51.3%  
BALANCE SHEET DATA
Current assets Rs m66,96824,167 277.1%   
Current liabilities Rs m40,2119,544 421.3%   
Net working cap to sales %27.174.3 36.5%  
Current ratio x1.72.5 65.8%  
Inventory Days Days8355 151.3%  
Debtors Days Days8129 282.9%  
Net fixed assets Rs m33,3229,514 350.3%   
Share capital Rs m282458 61.7%   
"Free" reserves Rs m55,77026,375 211.5%   
Net worth Rs m56,05226,832 208.9%   
Long term debt Rs m35,73825 142,950.0%   
Total assets Rs m132,88836,900 360.1%  
Interest coverage x4.41,305.5 0.3%   
Debt to equity ratio x0.60 68,430.1%  
Sales to assets ratio x0.70.5 139.2%   
Return on assets %9.59.8 97.0%  
Return on equity %16.513.4 123.0%  
Return on capital %17.820.4 87.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99822 281,242.9%   
Fx outflow Rs m22,8591,489 1,535.5%   
Net fx Rs m40,140-1,466 -2,737.5%   
CASH FLOW
From Operations Rs m13,2423,318 399.1%  
From Investments Rs m-6,990-2,383 293.3%  
From Financial Activity Rs m-7,387-1,104 669.5%  
Net Cashflow Rs m-2,971-169 1,763.1%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 6.9 7.5 92.0%  
FIIs % 34.4 4.9 702.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.7 44.3%  
Shareholders   56,727 85,207 66.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  SHASUN PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS